Treatment advances in non-Hodgkin’s lymphoma

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics, 2000. CA Cancer J. Clin. (2000) 50(1)7–33.
   Google Scholar
• HARRIS NL, JAFFE ES, STEIN H et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 84(5):1361–1392.
   PubMed Web of Science ®Google Scholar
• THE NON-HODGKINS LYMPHOMA CLASSIFICATION PROJECT: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood (1 9 97) 89(103909–3918.
   Google Scholar
• PILERI SA, MILANI M, FRATERNALI-ONCIONI G, SABATTINI E: From the REAL classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? Ann. Oncol. (1998) 9(6):607–612.
   Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting- Airlie house, Virginia, November 1997. J. Clin. Oncol. (1999) 17(12)3835–3849.
   Google Scholar
• ROSENBERG SA: The low-grade non-Hodgkin's lymphomas: challenges and opportunities. J. Clin. Oncol. (1985) 3(3):299–310.
   PubMedGoogle Scholar
• HOPPE RT, KUSHLAN P, KAPLAN HS, ROSENBERG SA, BROWN BW: The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood (1981) 58(3):592–598.
   PubMedGoogle Scholar
• SEYMOUR JF, MCLAUGHLIN P, FULLER LM etal.: High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann. Oncol. (1996) 7(2):157–163.
   Google Scholar
• SCHECHTER NR, PORTLOCK CS, YAHALOM J: Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J. Clin. Oncol. (1998) 16 (5):1916–1921.
   PubMed Web of Science ®Google Scholar
• NEUBAUER A, THIEDE C, MORGNER A et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J. Natl. Cancer Inst. (1997) 89(18) 1350–1355
   PubMedGoogle Scholar
• BOUABDALLAH R, XERRI L, BARDOU VJ et al.: Role ofinduction chemotherapy and bone marrow transplan-tation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann. Oncol. (1998) 96(6)619–625.
   Google Scholar
• SWEETENHAM JW, PEARCE R, TAGHIPOUR G, BLAISE D,GISSELBRECHT C, GOLDSTONE AH: Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma-outcome for patients treated with high-dose therapy and autolo-gous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J. Clin. Oncol (1996) 14(9)2465–2472.
   Google Scholar
• KURZROCK R, PILAT S, DUVIC M: Pentostatin therapy ofT-cell lymphomas with cutaneous manifestations. J. Clin. Oncol. (1999) 17(10):3117–3121.
   PubMedGoogle Scholar
• REDMAN JR, CABANILLAS F, VELASQUEZ WS et al.: PhaseII trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J. Clin. Oncol. (1992) 10(5):790–794.
   PubMed Web of Science ®Google Scholar
• HOCHSTER HS, KIM KM, GREEN MD et al: Activity offludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Coopera-tive Oncology Group study. J. Clin. Oncol. (1992) 10(1)28–32.
   Google Scholar
• SOLAL-CELIGNY P, BRICE P, BROUSSE N et al.: Phase IItrial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicentre study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. (1996) 14 (2) :514–519.
   PubMed Web of Science ®Google Scholar
• KAY AC, SAVEN A, CARRERA CJ et al.: 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. (1992) 10(3):371–377.
   PubMedGoogle Scholar
• SAVEN A, EMANUELE S, KOSTY M, KOZIOL J, ELLISON D,PIRO L: 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood (1995) 86(5):1710–1716.
   PubMedGoogle Scholar
• TULPULE A, SCHILLER G, HARVEY-BUCHANAN LA et al.:Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer (1998) 83(11)2370–2376.
   Google Scholar
• FORAN JM, OSCIER D, ORCHARD J et al.: Pharmacoki-netic study of single doses of oral fludarabine phosphate in patients with low-grade' non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. Clin. Oncol (1999) 17(5):1574–1579.
   Google Scholar
• KLASA R, MEYER R, SHUSTIK C, SAWKA C, SMITH A:Fludarabine versus CVP in previously treated patients with progressive low grade non-Hodgkin's lymphomas. Proc. Am. Soc. Clin. Oncol. (1999) 18:9a.
   Google Scholar
• •Preliminary results of the ECOG study using fludarabine with cyclophosphamide showing substantially longer PFS in patients with indolent NHL.
   Google Scholar
• MCLAUGHLIN P, HAGEMEISTER FB, ROMAGUERA JE et Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol. (1996) 14(4):1262–1268.
   PubMed Web of Science ®Google Scholar
• VELASQUEZ W, LEWD, MILLER T, FISHER R: SWOG 95-01: A Phase II trial of a combination of fludarabine and mitoxantrone in unteated advanced low-grade lymphoma: an effective, well tolerated therapy. Proc. Am. Soc. Clin. Oncol (1999) 18:9a.
   Google Scholar
• HOCHSTER H, OKEN M, WINTER J et al.: Prolonged time to progression in patients with low grade lymphoma treated with cyclophosphamide and fludarabine (ECOG 1491). Proc. Am. Soc. Clin. Oncol. (1998) 17:17a.
   Google Scholar
• SEZER 0, EUCKER J, MERGENTHALER HG et al. Fludara- bine and cyclophosphamide result in a high remission rate with moderate toxicity in low grade non-Hodgkin's lymphomas. Blood (1999) 94(10 Suppl 1):96a.
   Google Scholar
• SONNEVELD P, DE RIDDER M, VAN DER LELIE H et al: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J. Clin. Oncol (1995) 13(10):2530–2539.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH D: Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma. Leukemia Lymphoma (1993) 10(Suppl.):65–72.
   Google Scholar
• KRAUT EH, BALCERZAK SP, YOUNG D: A Phase II study of topotecan in non-Hodgkin's lymphoma: a Ohio State Phase 2 consortium study. Proc. Am. Soc. Clin. Oncol. (1998) 17:29a.
   Google Scholar
• WILSON WH, LITTLE R, PEARSON D et al: Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. J. Clin. Oncol (1998) 16(7):2345–2351.
   PubMedGoogle Scholar
• YOUNES A, AYOUB JP, SARRIS A et al: Paclitaxel activity for the treatment of non-Hodgkins lymphoma - final report of a Phase II trial. Br. J. Haematol. (1997) 96(2)328–332.
   Google Scholar
• BUDMAN DR, PETRONI GR, JOHNSON JL et al.: Phase IItrial of docetaxel in non-Hodgkin's lymphomas- a study of the Cancer and Leukemia Group B. J. Clin. Oncol. (1997) 15(103275–3279.
   Google Scholar
• YOUNES A, RODRIGUEZ MA, MCLAUGHLIN P etal. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leukemia Lymphoma (1997) 26(1-2):77–82.
   Google Scholar
• GLANTZ MJ, LAFOLLETTE S, JAECKLE KA et al. Random- ized trial of a slow-release versus a standard formula-tion of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. (1999) 17(103110–3116.
   Google Scholar
• ZINZANI PL, MAGAGNOLI M, BENDADI M et al.: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann. Oncol (1998) 9(12):1351–1353.
   PubMed Web of Science ®Google Scholar
• BERNELL P, OHM L: Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br. J. Haematol (1998) 101(1):203–204.
   PubMed Web of Science ®Google Scholar
• GARRETT TJ, RULE SA, MATCZAK E et al.: Gemcitabinefor relapsed or resistant lymphoma. Proc. Am. Soc. Clin. Oncol. (1999) 18:28a.
   Google Scholar
• ZINZANI PL, BALIVA G, BENDANDI M, GHERLINZONI F,TURA S: Therapy with gemcitabine in 44 pretreated peripheral T-cell lymphoma patients. Blood (1999) 94(10 Suppl. 1):659a.
   Google Scholar
• KURTZBERG J, KEATING M, MOORE JO: 2-amino-9-beta-n-arabinosy1-6-methoxy-9H-guanine (GW 506U: compound 506U) is highly active in patients with T-cell malignancies: results of a Phase I trial in pediatric and adult patients with refractory hemato-logical malignancies. Blood (1996) 88(1 Suppl):669a.
   Google Scholar
• GANDHI V, PLUNKETT W, RODRIGUEZ CO et al.: Compound GW506U78 in refractory hematologic malignancies-relationship between cellular pharma-cokinetics and clinical response. J. Clin. Oncol (1998) 16(10:3607–3615.
   PubMedGoogle Scholar
• DAVIS TA, MALONEY DG, CZERWINSKI DK, LILES TM, LEVY R: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 92(4):1184–1190.
   PubMed Web of Science ®Google Scholar
• REFF ME, CARNER K, CHAMBERS KS: Depletion of B cellsin vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83(2):435–445.
   PubMed Web of Science ®Google Scholar
• MATHAS S, BOMMERT K, DORKEN B, MAPARA MY: Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation. Blood (1998) 92 (Suppl. 1):405a.
   Google Scholar
• MALONEY DG, LILES TM, CZERWINSKI DK et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monocloncal antibody (IDCE-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 84 (8) 2457–2466.
   PubMed Web of Science ®Google Scholar
• MALONEY DC, GRILLO-LOPEZ AJ, BODKIN DJ et al.: IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15(10)3266–3274.
   Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• ••Pivotal Phase II trial of rituximab in relapsed low-gradelymphoma.
   Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood (1997) 90 (6):2188–2195.
   PubMed Web of Science ®Google Scholar
• GRILLO-LOPEZ AJ, MCLAUGHLIN P, CHESON BD et al.:First report on the application of the new criteria proposed for NHL: the Rituximab Pivotal trial. Proc. Am. Soc. Clin. Oncol (1999) 18:13a.
   Google Scholar
• PIRO LD, WHITE CA, GRILLO-LOPEZ AJ et al.: Extendedrituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1999) 10 (6) :655–661.
   PubMed Web of Science ®Google Scholar
• BERINSTEIN NL, GRILLO-LOPEZ AJ, WHITE CA et al. Association of serum rituximab (IDEC-C2B8) concen-tration and anti-tumor response in the treatment of recurrent low grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1998) 9(9):995–1001.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, BURIS HA, SCULLIN DC, MORRISSEYLH, LITCHEY S, GRECO FA: Rituximab induction and maintenance therapy in patients with previously untreated low-grade non-Hodgkin's lymphoma: preliminary results of a Minnie Pearl Cancer research Network Phase II trial. Proc. Am. Soc. Clin. Oncol. (1999) 18:29a.
   Google Scholar
• DAVIS TA, WHITE CA, GRILLO-LOPEZ AJ et al.: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. j Clin. Oncol (1999) 17(6):1851–1857.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, HAIOUN C, KETTERER N et al.: Rituximab(anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92 (6) :1927–1932.
   PubMed Web of Science ®Google Scholar
• •Phase II study of rituximab in relapsed aggressive lymphoma showing a 31% response rate despite higher doses and longer durations of therapy.
   Google Scholar
• FORAN JM, ROHATINER AZ, CUNNINGHAM D et al.: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocy-toma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. (2000) 18(2):317–324.
   PubMed Web of Science ®Google Scholar
• WINKLER U, JENSEN M, MANZKE 0, SCHULZ H, DIEHL V,ENGERT A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood (1999) 94(7):2217–2224.
   PubMed Web of Science ®Google Scholar
• BYRD JC, WASELENKO JK, MANEATIS TJ et al.: Rituximabtherapy in hematologic malignanciy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol (1999) 17(3):791–795.
   PubMed Web of Science ®Google Scholar
• BYRD JC, GREVER MR, DAVIS B et al.: Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a feasible and active regimen. Blood (1999) 94(10 Suppl. 1):704a.
   Google Scholar
• •Interesting new schedule of rituximab resulting in higher response rates in patients with chronic lymphocytic leukae-mias and small lymphocytic lymphomas (ORR: 46% and 60%, respectively).
   Google Scholar
• O'BRIEN SM, THOMAS DA, FREIREICH EM, ANDREEFF M, GILES FJ, KEATING MJ: Rittman has significant activity in patients with CLL. Blood (1999) 94(10 Suppl. 1):603a.
   Google Scholar
• •A dose-response relationship observed with 80% response rates in CLL patients treated with 2250 mg/m2.
   Google Scholar
• DEMIDEM A, LAM T, HARIHARAN AS, HANNA N, BONAVIDA B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. (1997) 12 (3) :177–186.
   PubMedGoogle Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol (1999) 17 (1) :268–276.
   PubMed Web of Science ®Google Scholar
• •Rituximab in combination with CHOP chemotherapy resulted in a 95% response rate in patients with relapsed low-grade lymphoma.
   Google Scholar
• CZUCZMAN MS, JONAS C, STEPHAN M et al.: Pilot study of Rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (1999) 18:17a.
   Google Scholar
• VOSE JM, LINK BK, GROSSBARD ML et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade non-Hodgkin's lymphoma. Ann. Oncol. (1999) 10\(Suppl. 3):58.
   Google Scholar
• KUYU H, KEUNG YK, RADFORD JE et al.: Efficacy of rituximab in relapsed low-grade B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Blood (1999) 94(10 Suppl. 1):172a.
   Google Scholar
• FLINN IW, O'DONNELL PO, NOGA SJ et al.: In vivo purging with rituximab during stem cell transplanta-tion for indolent lymphoma. Blood (1999) 94(10 Suppl. 1):638a.
   Google Scholar
• LUNDIN J, OSTERBORG A, BRITTANGER G et al.: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. (1998) 16(103257–3263.
   Google Scholar
• LIU SY, EARY JF, PETERSDORF SH et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol. (1998) 16(10)3270–3278.
   Google Scholar
• KAMINSKY MS, ZASADNY KR, FRANCIS IR et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol (1996) 14(7):1974–1981.
   PubMedGoogle Scholar
• WITZIG TE, WHITE CA, WISEMAN GA et al.: Phase I/IItrial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. (1999) 17(12):3793–3803.
   PubMed Web of Science ®Google Scholar
• •Defined the MTD of IDEC-Y2B8 at 0.4 mCi/kg with an ORR of 67% in B-cell NHL.
   Google Scholar
• WITZIG TE, WHITE CA, GORDON LI et al. Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results. Blood (1999) 94(10 Suppl 1):631.
   Google Scholar
• BRICE P, BASTION Y, LEPAGE E et al.: Comparison in low-tumor-burden follicular lymphomas between initial no-treatment policy, prednimustine, or interferon alpha: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. (1997) 15 (3):1110–1117.
   PubMed Web of Science ®Google Scholar
• HORNING SJ, MERIGAN TC, KROWN SE et al.: Human interferon alpha in malignant lymphoma and Hodgkin's disease. Cancer (1985) 56(6):1305–1310.
   PubMedGoogle Scholar
• DANA BW, UNGER J, FISHER RI: A randomized study of alpha-interferon consolidated in patients with low-grade lymphoma who responded to ProMACE-MOPP (SWOG 8809). Proc. Am. Soc. Clin. Oncol. (1998) 17:3a.
   Google Scholar
• PETERSON BA, PETRONI G, OKEN MM, JOHNSON JL, BARCOS M, COOPER MR: Cyclophosphamide versus cyclophosphamide plus interferon alpha-2b in follicular low-grade lymphomas: an intergroup Phase III trial (CALGB 8691 and EST 7486). Proc. Am. Soc. Clin. Oncol. (1997) 16:14a.
   Google Scholar
• HAGENBEEK A, CARDE P, MEERWALDT JH et al: Mainte- nance of remission with human recombitant interferon alpha-2a in patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J. Clin. Oncol (1998) 16(1):41–47.
   Google Scholar
• ARRANZ R, GARCIA-ALFONSO P, SOBRINO P et al.: Role of interferon alpha-2b in the induction and mainte-nance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J. Clin. Oncol. (1998) 16 (4): 1538–1546.
   PubMedGoogle Scholar
• SMALLEY R, WELLER E, HAWKINS M et al.: Alpha interferon in non-Hodgkin's lymphoma - an update of the ECOG I-COPA trial (E6484). Blood (1998) 92(1 Suppl):486a.
   Google Scholar
• SOLAL-CELIGNY P, LEPAGE E, BROUSSE N et al.: Doxorubicin-containing regimen with or without interferon alpha-2b for advanced follicular lympho-mas- final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. Clin. Oncol. (1998) 16(7):2332–2338.
   Web of Science ®Google Scholar
• •Survival benefit demonstrated with the addition of IFN to a doxorubicin-containing regimen in indolent NHL.
   Google Scholar
• WEBB A, CUNNINGHAM D, COTTER F et al. BCL-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet (1997) 349(9059):1137–1141
   PubMedGoogle Scholar
• HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specificidiotype vaccines in the treatment of patients with B-cell lymphoma- Long term results of a clinical trial. Blood (1997) 89(9):3129–3135.
   PubMed Web of Science ®Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination ofpatients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. (1996) 2(1):52–58.
   PubMed Web of Science ®Google Scholar
• •The first human study on vaccines using dendritic cells pulsed with tumour-specific idiotypic protein eliciting specific cellular antitumour immune responses.
   Google Scholar
• MACMANUS MP, HOPPE RT: Is radiotherapy curative forstage I and 1110w-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol. (1996) 14(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• SWEETENHAM J, HIEKE K, KERRIGAN M et al.:Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. Br. J. Haematol. (1999) 106(0:47–54.
   Google Scholar
• BURCHMORE MJ, DOWDEN S: One year cost of treatment of rituximab compared to fludarabine for relapsed or refractory, low-grade or follicular non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (1999) 18:25a.
   Google Scholar
• BIERMAN PJ, VOSE JM, ANDERSON JR, BISHOP MR, KESSINGER A, ARMITAGE JP: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15(2):445–50.
   PubMed Web of Science ®Google Scholar
• GRIBBEN JG: Bone marrow transplantation forlow-grade B-cell malignancies. Curr. Opin. Oncol. (1997) 9(2):117–121.
   PubMedGoogle Scholar
• •A good review on the use of high-dose therapy for indolent lymphomas.
   Google Scholar
• APOSTOLIDIS J, FORAN JM, JOHNSON PW et al.: Patternsof outcome following recurrence after myeloablative therapy with autologous bone marrow transplanta-tion for follicular lymphoma. J. Clin. Oncol. (1999) 17 (1):216–221.
   PubMed Web of Science ®Google Scholar
• VERDONCK LF, DEKKER AW, LOKHORST HM, PETERSONEJ, NIEUWENHUIS HK: Allogeneic versus autologous bone marow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood (1997) 90(104201–4205.
   Google Scholar
• VAN BESIEN K, SOBOCINSKI KA, ROWLINGS PA et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood (1998) 92(5):1832–1836.
   PubMed Web of Science ®Google Scholar
• ••The International Bone Marrow Transplantation Registryreport on 155 patients with indolent lymphomas treated with allogeneic transplantation showing low recurrence rates.
   Google Scholar
• FISHER RI, GAYNOR ER, DAHLBERG S et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl. J. Med. (1993) 328(14):1002–1006.
   PubMed Web of Science ®Google Scholar
• ••CHOP remains the standard therapy for newly diagnosedaggressive lymphomas.
   Google Scholar
• GORDON LI, HARRINGTON D, ANDERSEN J: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl. J. Med. (1992) 327(19):1342–1349.
   PubMedGoogle Scholar
• MILLER TP, DAHLBERG S, CASSADY JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl. J. Med. (1998) 339(1):21–26.
   PubMed Web of Science ®Google Scholar
• THE INTERNATIONAL NON-HODGKIN'S LYMPHOMA PROGNOSTIC FACTORS PROJECT: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl. J. Med. (1993) 329(14):987–994.
   Google Scholar
• ••Important project validating the International PrognosticIndex in aggressive lymphomas.
   Google Scholar
• SHIPP MA, ABELOFF MD, ANTMAN KH et al.: Interna- tional consensus conference on high-dose therapy with hematologic stem cell transplantation in aggres-sive non-Hodgkin's lymphoma: Report of the jury. J. Clin. Oncol. (1999) 17(0:423–429.
   PubMedGoogle Scholar
• ••A good overview of high-dose therapy with bone marrow orstem cell transplantation in various clinical settings for non-Hodgkin's lymphoma.
   Google Scholar
• HAIOUN C, LEPAGE E, GISSELBRECT C et al.: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. (1997) 15 (3):1131–1137.
   PubMed Web of Science ®Google Scholar
• •Survival benefit seen on retrospective analysis for HDT in a subset of high-risk newly diagnosed aggressive NHL.
   Google Scholar
• SANTINI G, SALVAGNO L, LEONI PVACOP-B versusVACOP-B plus autologous bone marrow transplanta-tion for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. Clin. Oncol. (1998) 16(8):2796–2802.
   Google Scholar
• GIANNI AM, BREGNI M, SIENA S et al.: High-dosechemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggres-sive B-cell lymphoma. N. Engl. J. Med. (1997) 336(18)1290–1297.
   Google Scholar
• •The use if upfront HDT as initial therapy for aggressive NHLL showed a superior 7-year PFS compared to conven-tional MACOP-B. However, no survival advantage was seen.
   Google Scholar
• PHILIP T, GUGLIELMI C, HAGENBEEK A et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy- sensitive non-Hodgkin's lymphoma. N Engl. J. Med. (1995) 333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• ••This study establishes the role of high dose chemotherapywith transplantation as standard salvage therapy for chemosensitive relapsed aggressive non-Hodgkin's lymphoma.
   Google Scholar